<DOC>
	<DOCNO>NCT00424021</DOCNO>
	<brief_summary>AMB-220-E international , multicenter , open-label study examine long-term safety ambrisentan ( BSF 208075 ) subject previously complete Myogen study NCT00046319 , `` A Phase II , Randomized , Double-Blind , Dose-Controlled , Dose-Ranging , Multicenter Study BSF 208075 Evaluating Exercise Capacity Subjects Moderate Severe Pulmonary Arterial Hypertension '' .</brief_summary>
	<brief_title>Phase 2 Extension Study Ambrisentan Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Must complete Visit 14/Week 24 NCT00046319 study . Women childbearing potential must negative urine pregnancy test Screening/Enrollment Visit agree use reliable double barrier method contraception study completion &gt; =4 week follow final study visit . Must complete Downtitration Period NCT00046319 prior enrollment AMB220E meet follow additional criterion : Subjects diagnosis HIV must stable disease status time Screening/Enrollment . Must stable conventional therapy PAH &gt; =4 week prior Screening Visit . Chronic prostanoid therapy , investigational prostacyclin derivative within 4 week prior Screening Visit . Intravenous inotrope use within 2 week prior Screening Visit . Females pregnant breastfeeding . Contraindication treatment endothelin receptor antagonist ( ERA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>